ClinicalTrials.gov

History of Changes for Study: NCT01772472
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy
Latest version (submitted September 19, 2022) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 January 17, 2013 None (earliest Version on record)
2 January 21, 2013 Contacts/Locations and Study Status
3 January 30, 2013 Contacts/Locations, Sponsor/Collaborators and Study Status
4 February 4, 2013 Study Status, Contacts/Locations and Study Identification
5 February 11, 2013 Contacts/Locations and Study Status
6 February 19, 2013 Contacts/Locations and Study Status
7 February 25, 2013 Contacts/Locations and Study Status
8 March 4, 2013 Contacts/Locations and Study Status
9 March 11, 2013 Recruitment Status, Contacts/Locations and Study Status
10 March 18, 2013 Contacts/Locations and Study Status
11 March 25, 2013 Contacts/Locations and Study Status
12 April 1, 2013 Contacts/Locations and Study Status
13 April 8, 2013 Contacts/Locations and Study Status
14 April 15, 2013 Contacts/Locations and Study Status
15 April 22, 2013 Contacts/Locations and Study Status
16 April 29, 2013 Contacts/Locations and Study Status
17 May 7, 2013 Contacts/Locations and Study Status
18 May 13, 2013 Contacts/Locations and Study Status
19 May 23, 2013 Contacts/Locations and Study Status
20 May 30, 2013 Contacts/Locations and Study Status
21 June 3, 2013 Study Status and Contacts/Locations
22 June 11, 2013 Contacts/Locations and Study Status
23 June 18, 2013 Contacts/Locations and Study Status
24 June 25, 2013 Contacts/Locations and Study Status
25 July 1, 2013 Contacts/Locations and Study Status
26 July 9, 2013 Contacts/Locations and Study Status
27 July 16, 2013 Contacts/Locations and Study Status
28 July 23, 2013 Contacts/Locations and Study Status
29 July 29, 2013 Contacts/Locations and Study Status
30 August 5, 2013 Contacts/Locations and Study Status
31 August 13, 2013 Contacts/Locations and Study Status
32 August 19, 2013 Contacts/Locations and Study Status
33 August 26, 2013 Contacts/Locations and Study Status
34 September 4, 2013 Contacts/Locations and Study Status
35 September 9, 2013 Contacts/Locations and Study Status
36 September 18, 2013 Contacts/Locations and Study Status
37 September 25, 2013 Contacts/Locations and Study Status
38 October 7, 2013 Contacts/Locations and Study Status
39 October 8, 2013 Contacts/Locations and Study Status
40 October 17, 2013 Contacts/Locations and Study Status
41 October 21, 2013 Contacts/Locations and Study Status
42 October 28, 2013 Contacts/Locations and Study Status
43 November 4, 2013 Contacts/Locations and Study Status
44 November 13, 2013 Contacts/Locations and Study Status
45 November 18, 2013 Contacts/Locations and Study Status
46 November 25, 2013 Contacts/Locations and Study Status
47 December 3, 2013 Study Status and Contacts/Locations
48 December 9, 2013 Contacts/Locations and Study Status
49 December 17, 2013 Contacts/Locations and Study Status
50 January 6, 2014 Contacts/Locations and Study Status
51 January 13, 2014 Contacts/Locations and Study Status
52 January 20, 2014 Contacts/Locations, Sponsor/Collaborators and Study Status
53 January 27, 2014 Contacts/Locations and Study Status
54 February 3, 2014 Study Status and Contacts/Locations
55 February 10, 2014 Contacts/Locations and Study Status
56 February 17, 2014 Contacts/Locations, Sponsor/Collaborators and Study Status
57 February 24, 2014 Contacts/Locations and Study Status
58 March 3, 2014 Contacts/Locations and Study Status
59 March 14, 2014 Contacts/Locations and Study Status
60 March 17, 2014 Contacts/Locations and Study Status
61 March 24, 2014 Contacts/Locations and Study Status
62 March 31, 2014 Contacts/Locations and Study Status
63 April 7, 2014 Study Status and Contacts/Locations
64 April 14, 2014 Contacts/Locations and Study Status
65 April 22, 2014 Contacts/Locations and Study Status
66 April 28, 2014 Contacts/Locations and Study Status
67 May 5, 2014 Study Status and Contacts/Locations
68 May 12, 2014 Contacts/Locations and Study Status
69 May 19, 2014 Contacts/Locations and Study Status
70 May 26, 2014 Contacts/Locations and Study Status
71 June 23, 2014 Contacts/Locations, Study Status and Study Description
72 June 30, 2014 Contacts/Locations and Study Status
73 July 7, 2014 Contacts/Locations and Study Status
74 July 14, 2014 Contacts/Locations and Study Status
75 July 21, 2014 Contacts/Locations and Study Status
76 July 28, 2014 Contacts/Locations and Study Status
77 August 4, 2014 Study Status and Contacts/Locations
78 August 11, 2014 Contacts/Locations and Study Status
79 August 19, 2014 Contacts/Locations and Study Status
80 August 26, 2014 Contacts/Locations and Study Status
81 September 22, 2014 Study Status
82 October 6, 2014 Study Status
83 October 13, 2014 Contacts/Locations and Study Status
84 October 20, 2014 Contacts/Locations and Study Status
85 November 3, 2014 Contacts/Locations and Study Status
86 November 10, 2014 Contacts/Locations and Study Status
87 November 17, 2014 Contacts/Locations and Study Status
88 November 24, 2014 Contacts/Locations and Study Status
89 December 1, 2014 Study Status
90 December 8, 2014 Contacts/Locations and Study Status
91 December 15, 2014 Contacts/Locations and Study Status
92 December 23, 2014 Contacts/Locations and Study Status
93 December 29, 2014 Contacts/Locations and Study Status
94 January 6, 2015 Contacts/Locations and Study Status
95 January 12, 2015 Contacts/Locations, Study Description and Study Status
96 January 19, 2015 Contacts/Locations, Study Description and Study Status
97 February 5, 2015 Contacts/Locations, Study Status and Study Description
98 February 19, 2015 Contacts/Locations and Study Status
99 February 23, 2015 Contacts/Locations and Study Status
100 March 2, 2015 Study Status
101 March 9, 2015 Contacts/Locations and Study Status
102 March 16, 2015 Contacts/Locations and Study Status
103 March 23, 2015 Contacts/Locations and Study Status
104 April 2, 2015 Contacts/Locations and Study Status
105 May 5, 2015 Study Status
106 May 11, 2015 Contacts/Locations and Study Status
107 May 29, 2015 Contacts/Locations and Study Status
108 June 1, 2015 Study Status and Contacts/Locations
109 July 1, 2015 Contacts/Locations and Study Status
110 July 31, 2015 Contacts/Locations and Study Status
111 August 17, 2015 Contacts/Locations and Study Status
112 September 1, 2015 Contacts/Locations and Study Status
113 September 9, 2015 Contacts/Locations and Study Status
114 October 1, 2015 Study Status and Contacts/Locations
115 November 2, 2015 Contacts/Locations and Study Status
116 December 1, 2015 Contacts/Locations and Study Status
117 December 31, 2015 Contacts/Locations and Study Status
118 February 1, 2016 Contacts/Locations and Study Status
119 March 1, 2016 Contacts/Locations, Study Status and Study Design
120 April 2, 2016 Recruitment Status, Contacts/Locations, Study Status and Study Design
121 May 4, 2016 Study Status
122 June 1, 2016 Study Status and Contacts/Locations
123 July 1, 2016 Study Status
124 July 29, 2016 Contacts/Locations, Eligibility, Outcome Measures, Study Design and Study Status
125 August 1, 2016 Study Status, Outcome Measures and Study Design
126 September 1, 2016 Study Status
127 October 3, 2016 Recruitment Status, Study Status, Contacts/Locations and Study Design
128 November 1, 2016 Recruitment Status, Contacts/Locations, Study Status and Study Design
129 June 14, 2017 Contacts/Locations and Study Status
130 July 11, 2017 Study Status
131 October 12, 2017 Contacts/Locations and Study Status
132 January 22, 2018 Contacts/Locations and Study Status
133 April 24, 2018 Contacts/Locations and Study Status
134 June 4, 2018 Contacts/Locations and Study Status
135 July 30, 2018 Study Status
136 October 29, 2018 Study Status and Contacts/Locations
137 February 1, 2019 Study Status and Contacts/Locations
138 June 1, 2019 Contacts/Locations, Study Status
Show
Results Submission Events
139 September 9, 2019 Outcome Measures, Study Status, Contacts/Locations, Study Design, Document Section and Results
140 October 31, 2019 Contacts/Locations and Study Status
141 January 29, 2020 Contacts/Locations, Study Status and Study Identification
142 April 24, 2020 Contacts/Locations and Study Status
143 July 21, 2020 Contacts/Locations and Study Status
144 March 31, 2021 Contacts/Locations and Study Status
145 June 24, 2021 Study Status, Contacts/Locations and Oversight
146 July 9, 2021 Outcome Measures, Study Status and Contacts/Locations
147 September 29, 2021 Contacts/Locations and Study Status
148 January 4, 2022 Contacts/Locations and Study Status
149 March 30, 2022 Contacts/Locations and Study Status
150 June 27, 2022 Study Status
151 September 19, 2022 Study Status and Contacts/Locations
Comparison Format:

Scroll up to access the controls

Study NCT01772472
Submitted Date:  January 17, 2013 (v1)

Open or close this module Study Identification
Unique Protocol ID: BO27938
Brief Title: A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy
Official Title: A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients With HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy
Secondary IDs: 2012-002018-37
Open or close this module Study Status
Record Verification: January 2013
Overall Status: Not yet recruiting
Study Start: March 2013
Primary Completion: August 2023 [Anticipated]
Study Completion: August 2023 [Anticipated]
First Submitted: January 17, 2013
First Submitted that
Met QC Criteria:
January 17, 2013
First Posted: January 21, 2013 [Estimate]
Last Update Submitted that
Met QC Criteria:
January 17, 2013
Last Update Posted: January 21, 2013 [Estimate]
Open or close this module Sponsor/Collaborators
Sponsor: Hoffmann-La Roche
Responsible Party: Sponsor
Collaborators:
Open or close this module Oversight
U.S. FDA-regulated Drug:
U.S. FDA-regulated Device:
Data Monitoring:
Open or close this module Study Description
Brief Summary: This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in the breast or axillary lymph nodes following preoperative therapy. Eligible patients will be randomized to receive either trastuzumab emtansine 3.6 mg/kg or trastuzumab 6 mg/kg intravenously every 3 weeks for 14 cycles. Radiotherapy and/or hormone therapy will be given in addition if indicated.
Detailed Description:
Open or close this module Conditions
Conditions: Breast Cancer
Keywords:
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 3
Interventional Study Model: Parallel Assignment
Number of Arms: 2
Masking: None (Open Label)
Allocation: Randomized
Enrollment: 1484 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: Trastuzumab emtansine Drug: trastuzumab emtansine
3.6 mg/kg intravenously every 3 weeks, 14 cycles
Active Comparator: Trastuzumab Drug: trastuzumab
6 mg/kg intravenously every 3 weeks, 14 cycles
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Invasive disease-free survival (IDFS): Time from randomization to ipsilateral invasive breast tumor recurrence, ipsilateral local-regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, or death of any cause
[ Time Frame: up to 10 years ]

Secondary Outcome Measures:
1. Invasive disease-free survival including second non-breast cancers
[ Time Frame: up to 10 years ]

2. Disease-free survival: Time from randomization to first occurrence of an IDFS event including second primary non-breast cancer or contralateral or ipsilateral ductal carcinoma in situ
[ Time Frame: up to 10 years ]

3. Overall survival: Time from randomization to death of any cause
[ Time Frame: up to 10 years ]

4. Distant recurrence-free interval: Time from randomization to date of distant breast cancer recurrence
[ Time Frame: up to 10 years ]

5. Safety: Incidence of adverse events
[ Time Frame: up to 10 years ]

6. Incidence of cardiac events: Death from cardiac cause or severe chronic heart failure (NYHA Class III or IV)
[ Time Frame: up to 10 years ]

7. Patient reported outcomes: European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Quetionnaire QLQ-C30/QLQ-BR23, EuroQol EQ-5d Questionnaire
[ Time Frame: up to 10 years ]

Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age:
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

Inclusion Criteria:

  • Adult patient, >/= 18 years of age
  • HER2-positive breast cancer
  • Histologically confirmed invasive breast carcinoma
  • Clinical stage T1-4/N0-3/M0 at presentation (patients with T1a/bN0 tumors will not be eligible)
  • Completion of preoperative systemic treatment consisting of at least 6 cycles with a total duration of at least 16 weeks, including at least 9 weeks of trastuzumab and at least 9 weeks of taxane-based therapy
  • Adequate excision: surgical removal of all clinically evident disease in the breast and lymph nodes as specified in protocol
  • Pathological evidence of residual invasive carcinoma in the breast or axillary lymph nodes following completion of preoperative therapy
  • An interval of no more than 12 weeks between the date of surgery and the date of randomization
  • Known hormone-receptor status
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Adequate hematologic, renal and liver function
  • Left ventricular ejection fraction (LVEF) >/= 50% at screening and no decrease in LVEF by more than 15% absolute points from pre-chemotherapy
  • Women of childbearing potential and men with partners of childbearing potential must be willing to use effective contraception as defined by protocol for the duration of study treatment and for at least 6 months after the last dose of study treatment
  • Documentation of hepatitis B virus and hepatitis C virus serology is required

Exclusion Criteria:

  • Stage IV (metastatic) breast cancer
  • History of any prior (ipsi- or contralateral breast cancer except lobular carcinoma in situ
  • Evidence of clinically evident gross residual or recurrent disease following preoperative therapy and surgery
  • Progressive disease during preoperative therapy
  • Treatment with any anti-cancer investigational drug within 28 days prior to commencing study treatment
  • History of other malignancy within the last 5 years except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other non-breast malignancies with a similar outcome to those mentioned above
  • Patients for whom radiotherapy would be recommended for breast cancer treatment but for whom it is contraindicated because of medical reasons
  • Current NCI CTCAE (Version 4.0) Grade >/= 2 peripheral neuropathy
  • History of exposure to the following cumulative doses of anthracyclines:

Doxorubicin > 240 mg/m2 Epirubicin > 480 mg/m2 For other anthracyclines, exposure equivalent to doxorubicin > 240 mg/m2

  • Cardiopulmonary dysfunction as defined by protocol
  • Prior treatment with trastuzumab emtansine
  • Current severe, uncontrolled systemic disease
  • Pregnant or lactating women
  • Any known active liver disease, e.g. due to HBV, HCV, autoimmune hepatic disorders, or sclerosing cholangitis
  • Concurrent serious uncontrolled infections or known infection with HIV
  • History of intolerance, including Grade 3 to 4 infusion reaction or hypersensitivity to trastuzumab or murine proteins
Open or close this module Contacts/Locations
Central Contact Person: Please reference Study ID Number: BO27938 www.roche.com/about_roche/roche_worldwide.htm
Telephone: 888-662-6728 (U.S. Only)
Email: genentechclinicaltrials@druginfo.com
Study Officials: Clinical Trials
Study Director
Hoffmann-La Roche
Locations: United States, California
Long Beach, California, United States, 90806
San Diego, California, United States, 92120
Stanford, California, United States, 94305
Vallejo, California, United States, 94589
United States, Colorado
Colorado Springs, Colorado, United States, 80909
Denver, Colorado, United States, 80205
Denver, Colorado, United States, 80224-2522
Wheat Ridge, Colorado, United States, 80033
United States, Connecticut
Hartford, Connecticut, United States, 6102
United States, Florida
Jacksonville, Florida, United States, 32207
Lakeland, Florida, United States, 33805
Miami Beach, Florida, United States, 33140
Orlando, Florida, United States, 32806
United States, Georgia
Albany, Georgia, United States, 31701
United States, Illinois
Plainfield, Illinois, United States, 60585
United States, Kentucky
Lexington, Kentucky, United States, 40536
Louisville, Kentucky, United States, 40202
United States, Maine
Bangor, Maine, United States, 04401
United States, Maryland
Baltimore, Maryland, United States, 21204
United States, Michigan
Detroit, Michigan, United States, 48202
Grand Rapids, Michigan, United States, 49503
Lansing, Michigan, United States, 48910
Royal Oak, Michigan, United States, 48073
United States, Minnesota
Saint Louis Park, Minnesota, United States, 55426
United States, Nevada
Las Vegas, Nevada, United States, 89106
United States, New Jersey
Long Branch, New Jersey, United States, 07740
New Brunswick, New Jersey, United States, 08901
Newark, New Jersey, United States, 07112
Sparta, New Jersey, United States, 07871-1791
United States, New York
Glenn Falls, New York, United States, 12801
New York, New York, United States, 10032
Stony Brook, New York, United States, 11794
Troy, New York, United States, 12180
United States, North Carolina
Charlotte, North Carolina, United States, 28204-2839
United States, North Dakota
Fargo, North Dakota, United States, 58122-9988
United States, Ohio
Akron, Ohio, United States, 44304
Cleveland, Ohio, United States, 52242-1086
Columbus, Ohio, United States, 43210
United States, Oregon
Portland, Oregon, United States, 97225
United States, Pennsylvania
Danville, Pennsylvania, United States, 17822
East Stroudsburg, Pennsylvania, United States, 18301
Philadelphia, Pennsylvania, United States, 19107
Philadelphia, Pennsylvania, United States, 19141
Pittsburgh, Pennsylvania, United States, 15212
Pittsburgh, Pennsylvania, United States, 15213
York, Pennsylvania, United States, 17403
United States, South Dakota
Sioux Falls, South Dakota, United States, 57104
Sioux Falls, South Dakota, United States, 57105
United States, Tennessee
Knoxville, Tennessee, United States, 37916-2305
United States, Texas
Houston, Texas, United States, 77030
Lubbock, Texas, United States, 79410
United States, Virginia
Fredericksburg, Virginia, United States, 22408
Lynchburg, Virginia, United States, 24501
Richmond, Virginia, United States, 23298
United States, Washington
Issaquah, Washington, United States, 98029
Seattle, Washington, United States, 98101
United States, West Virginia
Morgantown, West Virginia, United States, 26506-9162
United States, Wisconsin
Marshfield, Wisconsin, United States, 54449
Milwaukee, Wisconsin, United States, 53215
Argentina
Buenos Aires, Argentina, C1122AAL
La Rioja, Argentina, F5300COE
Rosario, Argentina, S2000KZE
Austria
Wien, Austria, 1090
Belgium
Gent, Belgium, 9000
Liege, Belgium, 4000
Wilrijk, Belgium, 2610
Brazil
Barretos, Brazil, 14784-400
Brasilia, Brazil, 70390-055
Brasilia, Brazil, 72110-150
Curitiba, Brazil, 80530-010
JAU, Brazil, 17210-120
Porto Alegre, Brazil, 90035-001
Porto Alegre, Brazil, 90540-140
Rio de Janeiro, Brazil, 20560-120
Rio de Janeiro, Brazil, 22290-160
Salvador, Brazil, 40170-110
Sao Jose Dos Campos, Brazil, 12245-750
Sao Paulo, Brazil, 01246-000
Sao Paulo, Brazil, 01321-000
Sao Paulo, Brazil, 01321-001
São Paulo, Brazil, 01236-030
Canada, Ontario
London, Ontario, Canada, N6A 4L6
Toronto, Ontario, Canada, M4N 3M5
Toronto, Ontario, Canada, M5B 1W8
Canada, Quebec
Greenfield Park, Quebec, Canada, J4V 2H1
Montreal, Quebec, Canada, H2W 1S6
Montreal, Quebec, Canada, H2W 1T8
Montreal, Quebec, Canada, H3G 1A4
Quebec City, Quebec, Canada, G1J 1Z4
China
Canton, China, 44710
Czech Republic
Hradec Kralove, Czech Republic, 500 05
Olomouc, Czech Republic, 775 20
Praha 2, Czech Republic, 128 08
France
Avignon, France, 84918
Besancon, France, 25030
Bordeaux, France, 33076
Bordeaux, France, 33077
Bourg En Bresse, France, 01012
Caen, France, 14076
Clermont Ferrand, France, 63011
Le Mans, France, 72015
Marseille, France, 13273
Montpellier, France, 34298
Paris, France, 75231
Paris, France, 75475
Paris, France, 75970
Rouen, France, 76038
St Cloud, France, 92210
Strasbourg, France, 67065
Villejuif, France, 94805
Germany
Berlin, Germany, 10367
Berlin, Germany, 13126
Berlin, Germany, 14169
Bielefeld, Germany, 33604
Böblingen, Germany, 71032
Chemnitz, Germany, 09116
Dortmund, Germany, 44137
Düsseldorf, Germany, 40235
Erlangen, Germany, 91054
Essen, Germany, 45122
Essen, Germany, 45136
Esslingen, Germany, 73730
Frankfurt, Germany, 60431
Frankfurt, Germany, 60596
Frankfurt Am Main, Germany, 60389
Freiburg, Germany, 79106
Fürth, Germany, 90766
Gelsenkirchen, Germany, 45879
Greifswald, Germany, 17487
Halle, Germany, 06110
Halle, Germany, 06120
Hamburg, Germany, 20357
Hamm, Germany, 59073
Hannover, Germany, 30177
Hannover, Germany, 30559
Hannover, Germany, 30625
Heidelberg, Germany, 69115
Kassel, Germany, 34125
Kiel, Germany, 24105
Koeln, Germany, 50935
Köln, Germany, 51067
Lebach, Germany, 66822
Limburg, Germany, 65549
München, Germany, 80337
München, Germany, 80638
Münster, Germany, 48149
Offenbach, Germany, 63069
Paderborn, Germany, 33098
Recklinghausen, Germany, 45657
Reutlingen, Germany, 72764
Rostock, Germany, 18059
Stralsund, Germany, 18435
Stuttgart, Germany, 70376
Traunstein, Germany, 83278
Tübingen, Germany, 72076
ULM, Germany, 89075
Wiesbaden, Germany, 65199
Witten, Germany, 58452
Würzburg, Germany, 97070
Greece
Heraklion, Greece, 71110
Hong Kong
Chai Wan, Hong Kong, 852
Hong Kong, Hong Kong, 852
Israel
Beer Sheva, Israel, 84101
Jerusalem, Israel, 91200
Ramat Gan, Israel, 52621
Italy
Brindisi, Italy, 72100
Candiolo, Italy, 10060
Cremona, Italy, 26100
Genova, Italy, 16132
Milano, Italy, 20132
Milano, Italy, 20133
Milano, Italy, 20141
Modena, Italy, 40124
Monza, Italy, 20052
Roma, Italy, 00189
Serbia
Belgrade, Serbia, 11000
Kragujevac, Serbia, 34000
Sremska Kamenica, Serbia, 21204
South Africa
Johannesburg, South Africa, 2193
Johannesburg, South Africa, 2196
Kraaifontein, South Africa, 7570
Pietermaritzburg, South Africa, 3201
Port Elizabeth, South Africa, 6045
Pretoria, South Africa, 0081
Spain
Alcorcon, Spain, 28922
Cádiz, Spain, 11009
Leganes, Spain, 28911
Madrid, Spain, 28046
Malaga, Spain, 29010
Navarra, Spain, 31008
Reus, Spain, 43204
Terrassa, Spain, 08221
Valencia, Spain, 41014
Valencia, Spain, 46017
Vigo, Spain, 36204
Sweden
Gävle, Sweden, 80187
Lund, Sweden, 22185
Stockholm, Sweden, 17176
Switzerland
Aarau, Switzerland, 5001
Zürich, Switzerland, 8008
Taiwan
Taichung, Taiwan, 407
Taipei, Taiwan, 100
Taipei, Taiwan, 105
Taipei, Taiwan, 112
Turkey
Bursa, Turkey, 16059
Istanbul, Turkey, 34000
Izmir, Turkey, 35100
Malatya, Turkey, 44280
Open or close this module IPDSharing
Plan to Share IPD:
Open or close this module References
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services